Yahoo
NasdaqGS - Nasdaq Real Time Price USD

First Tracks Biotherapeutics, Inc. (TRAX)

34.54 +0.41 (+1.20%)
As of 1:10:18 PM EDT. Market Open.
Chart Range Bar
Loading chart for TRAX
  • Previous Close 34.13
  • Open 34.26
  • Bid 26.06 x 200
  • Ask 43.84 x 200
  • Day's Range 33.99 - 36.30
  • 52 Week Range 14.72 - 49.91
  • Volume 789,312
  • Avg. Volume 830,828
  • Market Cap (intraday) 1.234B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.71
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 72.50
  • Zacks Rating
    Bearish

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

www.firsttracksbio.com

104

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/15/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TRAX
72.70%
S&P 500 (^GSPC)
12.91%

1-Year Return

TRAX
72.70%
S&P 500 (^GSPC)
15.86%

3-Year Return

TRAX
72.70%
S&P 500 (^GSPC)
78.60%

5-Year Return

TRAX
72.70%
S&P 500 (^GSPC)
72.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -50.48M
Profit Margin 0.00%

Q1

FY26

-50M
-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

57.00
72.50 Average
34.54 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 50 -> 60

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    1.31B

  • Enterprise Value

    1.15B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    7.76

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -160.3M

  • Diluted EPS (ttm)

    -4.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    168.02M

  • Total Debt/Equity (mrq)

    2.57%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

34.54 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: